Group structure
10 companies in 9 countries
Loading…
10 companies in 9 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
19 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BEQALZI1mg | 20mg | 5mg | 80mg · Tablet | Sonrotoclax | United States | Marketed | 2026 |
| BRUKINSA160 mg · Tablet | Zanubrutinib | Canada | Marketed | 2025 |
| BRUKINSA | Zanubrutinib | Brazil | Authorised | 2023 |
| Brukinsa | Zanubrutinib | EU (EMA) | Authorised | 2021 |
| BRUKINSA80 mg · Capsule | Zanubrutinib | Canada | Marketed | 2021 |
| BRUKINSA160mg · Tablet | Zanubrutinib | United States | Marketed | 2025 |
| BRUKINSA80mg · Capsule | Zanubrutinib | United States | Marketed | 2019 |
| BRUKINSA 160 MG COMPRIMIDOS RECUBIERTOS CON PELICULA160 mg · Comprimido recubierto con película | Zanubrutinib | Spain | Marketed | 2025 |
| BRUKINSA 80 MG CAPSULAS DURAS80 mg · Cápsula dura | Zanubrutinib | Spain | Authorised | 2021 |
| BRUKINSA 80 MG CAPSULAS DURAS80 mg · Cápsula dura | Zanubrutinib | Spain | Marketed | 2025 |
| BRUKINSA 80 MG CAPSULAS DURAS80 mg · Cápsula dura | Zanubrutinib | Spain | Marketed | 2026 |
| BRUKINSA™ CAPSULE 80MG80mg · Capsule | Zanubrutinib | Singapore | Authorised | 2021 |
| Brukinsa®80mg · kapsula, tvrda | Zanubrutinib | Serbia | Authorised | 2024 |
| Tevimbra | Tislelizumab | EU (EMA) | Authorised | 2023 |
| TEVIMBRA100 mg / 10 ml · Solution | Tislelizumab | Canada | Marketed | 2026 |
| Tevimbra150mg/15ml (10mg/ml) · Injection | Tislelizumab | United States | Marketed | 2026 |
| TEVIMBRA | Tislelizumab | Brazil | Authorised | 2024 |
| TEVIMBRA 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSION10 mg · Concentrado para solución para perfusión | Tislelizumab | Spain | Marketed | 2024 |
| TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML100mg/10mL · Infusion, solution concentrate | Tislelizumab | Singapore | Authorised | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 5 | 5 | 0 | CompaniesAll medicines |
| United States | 4 | 4 | 0 | CompaniesAll medicines |
| Canada | 3 | 3 | 0 | CompaniesAll medicines |
| Brazil | 2 | 2 | 0 | CompaniesAll medicines |
| European Union (EMA) | 2 | 2 | 0 | CompaniesAll medicines |
| Singapore | 2 | 2 | 0 | CompaniesAll medicines |
| Serbia | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Colombia, France, Italy, Malaysia, Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Agência Nacional de Vigilância Sanitária (Anvisa), DATAVISA open-data register; source modification 2026-10-07, acquired 2026-10-07 UTC.
Licence: Brazil federal open-data reuse, Decreto 8777/2016, consolidated article 4 as amended by Decreto 9903/2019
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026; publication updated 7 October 2026; source PDF periods January–September 2026; original bytes acquired 18 October 2026; PDF page/table/exact-authorisation projections by Prognia under OGL v3.0.
Licence: Open Government Licence v3.0; GOV.UK Crown copyright publication and linked factual MHRA grant registers
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep Beone’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.